Conduct Disorder Clinical Trial
Official title:
A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents
Verified date | November 2011 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Ministry of Health |
Study type | Interventional |
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of adolescents with conduct disorder.
Status | Completed |
Enrollment | 50 |
Est. completion date | October 2004 |
Est. primary completion date | October 2004 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Years to 16 Years |
Eligibility |
Inclusion Criteria: - History of conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified - Score >8 on the Impulsivity Rating Scale Exclusion Criteria: - Other serious medical or psychiatric conditions excluding conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified - Treatment with antiepileptic medications Other protocol-defined inclusion/exclusion criteria may apply. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Novartis |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage reduction on Impulsivity Rating Scale (IRS) | |||
Secondary | Percent reduction in the Modified Overt Aggression Scale (MOAS) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03535805 -
Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances
|
N/A | |
Recruiting |
NCT05449002 -
Digital Single Session Intervention for Youth Mental Health
|
N/A | |
Withdrawn |
NCT02247986 -
Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder
|
Phase 1/Phase 2 | |
Recruiting |
NCT04631042 -
Developing Brain, Impulsivity and Compulsivity
|
||
Completed |
NCT02485587 -
Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents
|
N/A | |
Completed |
NCT00819429 -
Supplements and Social Skills Intervention Study
|
N/A | |
Completed |
NCT00626236 -
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
|
Phase 2 | |
Completed |
NCT01085305 -
The Effectiveness of Parent-Child Interaction Therapy (PCIT)
|
N/A | |
Completed |
NCT00250354 -
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
|
Phase 3 | |
Completed |
NCT00000385 -
Long-Term Lithium Treatment for Aggressive Conduct Disorder
|
Phase 3 | |
Withdrawn |
NCT01443949 -
Teenagers, Drug Addiction, and Reward and Impulse Control
|
||
Completed |
NCT04091633 -
School Health Implementation Network: Eastern Mediterranean
|
N/A | |
Completed |
NCT02563145 -
Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents
|
N/A | |
Completed |
NCT02766101 -
Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges
|
N/A | |
Completed |
NCT00404911 -
Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth
|
N/A | |
Completed |
NCT00051727 -
Prevention of School Dropout for Mexican American Adolescents
|
Phase 2 | |
Completed |
NCT02998073 -
Investigating Psychosocial Intervention Treatment Response in Justice-Involved Youth With Conduct Disorder
|
N/A | |
Completed |
NCT03292848 -
Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders
|
Phase 1 | |
Recruiting |
NCT06373484 -
Matching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents
|
N/A | |
Recruiting |
NCT05637320 -
Big Feelings: A Study on Children's Emotions in Therapy
|
N/A |